APO Research
Talk to an analyst

APO RESEARCH · REPORT

Somatostatin Analogue Drug

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Somatostatin Analogue Drug Market Analysis and Forecast 2026-2032

30 December 2025192 pages

Choose your research edition.

Industry ResearchSomatostatin Analogue Drug Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Somatostatin Analogue Drug Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Somatostatin Analogue Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Somatostatin Analogue Drug Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Somatostatin Analogue Drug Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Somatostatin Analogue Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Somatostatin Analogue Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Somatostatin Analogue Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Somatostatin Analogue Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Somatostatin Analogue Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Somatostatin Analogue Drug include Teva Pharmaceutical Industries Ltd., Novartis AG, Eli Lilly & Co., Pfizer Inc., Tarveda Therapeutics Inc., Ipsen Group, F. Hoffmann-La Roche Ltd., Chiasma and Camurus AB, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Somatostatin Analogue Drug, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Somatostatin Analogue Drug, also provides the revenue of main regions and countries. Of the upcoming market potential for Somatostatin Analogue Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Somatostatin Analogue Drug revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Somatostatin Analogue Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Somatostatin Analogue Drug revenue, projected growth trends, production technology, application and end-user industry.

Somatostatin Analogue Drug Segment by Company

Teva Pharmaceutical Industries Ltd.

Novartis AG

Eli Lilly & Co.

Pfizer Inc.

Tarveda Therapeutics Inc.

Ipsen Group

F. Hoffmann-La Roche Ltd.

Chiasma

Camurus AB

Boehringer Ingelheim International GmbH

Somatostatin Analogue Drug Segment by Type

Octreotide

Lanreotide

Pasireotide

Somatostatin Analogue Drug Segment by Application

Acromegaly

Neuroendocrine Tumor (NET)

Others

Somatostatin Analogue Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Somatostatin Analogue Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Somatostatin Analogue Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Somatostatin Analogue Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Somatostatin Analogue Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Somatostatin Analogue Drug company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Somatostatin Analogue Drug revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Somatostatin Analogue Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Octreotide Major Player Table 3. Lanreotide Major Player Table 4. Pasireotide Major Player Table 5. Global Somatostatin Analogue Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Acromegaly Major Player Table 7. Neuroendocrine Tumor (NET) Major Player Table 8. Others Major Player Table 9. Somatostatin Analogue Drug Industry Trends Table 10. Somatostatin Analogue Drug Industry Drivers Table 11. Somatostatin Analogue Drug Industry Opportunities and Challenges Table 12. Somatostatin Analogue Drug Industry Restraints Table 13. Global Somatostatin Analogue Drug Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Somatostatin Analogue Drug Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Somatostatin Analogue Drug Market Share by Region (2021-2026) Table 16. Global Somatostatin Analogue Drug Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Somatostatin Analogue Drug Market Share by Region (2027-2032) Table 18. Global Somatostatin Analogue Drug Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Somatostatin Analogue Drug Revenue Market Share by Players (2021-2026) Table 20. Global Somatostatin Analogue Drug Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Somatostatin Analogue Drug Key Players Headquarters & Area Served Table 22. Global Somatostatin Analogue Drug Players, Product Type & Application Table 23. Global Somatostatin Analogue Drug Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Somatostatin Analogue Drug by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Somatostatin Analogue Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Somatostatin Analogue Drug Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Somatostatin Analogue Drug Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Somatostatin Analogue Drug Revenue Market Share by Type (2021-2026) Table 30. Global Somatostatin Analogue Drug Revenue Market Share by Type (2027-2032) Table 31. Global Somatostatin Analogue Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Somatostatin Analogue Drug Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Somatostatin Analogue Drug Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Somatostatin Analogue Drug Revenue Market Share by Application (2021-2026) Table 35. Global Somatostatin Analogue Drug Revenue Market Share by Application (2027-2032) Table 36. Teva Pharmaceutical Industries Ltd. Company Information Table 37. Teva Pharmaceutical Industries Ltd. Business Overview Table 38. Teva Pharmaceutical Industries Ltd. Somatostatin Analogue Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Teva Pharmaceutical Industries Ltd. Somatostatin Analogue Drug Product Portfolio Table 40. Teva Pharmaceutical Industries Ltd. Recent Development Table 41. Novartis AG Company Information Table 42. Novartis AG Business Overview Table 43. Novartis AG Somatostatin Analogue Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Novartis AG Somatostatin Analogue Drug Product Portfolio Table 45. Novartis AG Recent Development Table 46. Eli Lilly & Co. Company Information Table 47. Eli Lilly & Co. Business Overview Table 48. Eli Lilly & Co. Somatostatin Analogue Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Eli Lilly & Co. Somatostatin Analogue Drug Product Portfolio Table 50. Eli Lilly & Co. Recent Development Table 51. Pfizer Inc. Company Information Table 52. Pfizer Inc. Business Overview Table 53. Pfizer Inc. Somatostatin Analogue Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Pfizer Inc. Somatostatin Analogue Drug Product Portfolio Table 55. Pfizer Inc. Recent Development Table 56. Tarveda Therapeutics Inc. Company Information Table 57. Tarveda Therapeutics Inc. Business Overview Table 58. Tarveda Therapeutics Inc. Somatostatin Analogue Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Tarveda Therapeutics Inc. Somatostatin Analogue Drug Product Portfolio Table 60. Tarveda Therapeutics Inc. Recent Development Table 61. Ipsen Group Company Information Table 62. Ipsen Group Business Overview Table 63. Ipsen Group Somatostatin Analogue Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Ipsen Group Somatostatin Analogue Drug Product Portfolio Table 65. Ipsen Group Recent Development Table 66. F. Hoffmann-La Roche Ltd. Company Information Table 67. F. Hoffmann-La Roche Ltd. Business Overview Table 68. F. Hoffmann-La Roche Ltd. Somatostatin Analogue Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. F. Hoffmann-La Roche Ltd. Somatostatin Analogue Drug Product Portfolio Table 70. F. Hoffmann-La Roche Ltd. Recent Development Table 71. Chiasma Company Information Table 72. Chiasma Business Overview Table 73. Chiasma Somatostatin Analogue Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Chiasma Somatostatin Analogue Drug Product Portfolio Table 75. Chiasma Recent Development Table 76. Camurus AB Company Information Table 77. Camurus AB Business Overview Table 78. Camurus AB Somatostatin Analogue Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Camurus AB Somatostatin Analogue Drug Product Portfolio Table 80. Camurus AB Recent Development Table 81. Boehringer Ingelheim International GmbH Company Information Table 82. Boehringer Ingelheim International GmbH Business Overview Table 83. Boehringer Ingelheim International GmbH Somatostatin Analogue Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Boehringer Ingelheim International GmbH Somatostatin Analogue Drug Product Portfolio Table 85. Boehringer Ingelheim International GmbH Recent Development Table 86. North America Somatostatin Analogue Drug Revenue by Type (2021-2026) & (US$ Million) Table 87. North America Somatostatin Analogue Drug Revenue by Type (2027-2032) & (US$ Million) Table 88. North America Somatostatin Analogue Drug Revenue by Application (2021-2026) & (US$ Million) Table 89. North America Somatostatin Analogue Drug Revenue by Application (2027-2032) & (US$ Million) Table 90. North America Somatostatin Analogue Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 91. North America Somatostatin Analogue Drug Revenue by Country (2021-2026) & (US$ Million) Table 92. North America Somatostatin Analogue Drug Revenue by Country (US$ Million) & (2027-2032) Table 93. Europe Somatostatin Analogue Drug Revenue by Type (2021-2026) & (US$ Million) Table 94. Europe Somatostatin Analogue Drug Revenue by Type (2027-2032) & (US$ Million) Table 95. Europe Somatostatin Analogue Drug Revenue by Application (2021-2026) & (US$ Million) Table 96. Europe Somatostatin Analogue Drug Revenue by Application (2027-2032) & (US$ Million) Table 97. Europe Somatostatin Analogue Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 98. Europe Somatostatin Analogue Drug Revenue by Country (2021-2026) & (US$ Million) Table 99. Europe Somatostatin Analogue Drug Revenue by Country (US$ Million) & (2027-2032) Table 100. China Somatostatin Analogue Drug Revenue by Type (2021-2026) & (US$ Million) Table 101. China Somatostatin Analogue Drug Revenue by Type (2027-2032) & (US$ Million) Table 102. China Somatostatin Analogue Drug Revenue by Application (2021-2026) & (US$ Million) Table 103. China Somatostatin Analogue Drug Revenue by Application (2027-2032) & (US$ Million) Table 104. Asia Somatostatin Analogue Drug Revenue by Type (2021-2026) & (US$ Million) Table 105. Asia Somatostatin Analogue Drug Revenue by Type (2027-2032) & (US$ Million) Table 106. Asia Somatostatin Analogue Drug Revenue by Application (2021-2026) & (US$ Million) Table 107. Asia Somatostatin Analogue Drug Revenue by Application (2027-2032) & (US$ Million) Table 108. Asia Somatostatin Analogue Drug Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 109. Asia Somatostatin Analogue Drug Revenue by Region (US$ Million) & (2021-2026) Table 110. Asia Somatostatin Analogue Drug Revenue by Region (US$ Million) & (2027-2032) Table 111. SAMEA Somatostatin Analogue Drug Revenue by Type (2021-2026) & (US$ Million) Table 112. SAMEA Somatostatin Analogue Drug Revenue by Type (2027-2032) & (US$ Million) Table 113. SAMEA Somatostatin Analogue Drug Revenue by Application (2021-2026) & (US$ Million) Table 114. SAMEA Somatostatin Analogue Drug Revenue by Application (2027-2032) & (US$ Million) Table 115. SAMEA Somatostatin Analogue Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 116. SAMEA Somatostatin Analogue Drug Revenue by Country (2021-2026) & (US$ Million) Table 117. SAMEA Somatostatin Analogue Drug Revenue by Country (US$ Million) & (2027-2032) Table 118. Research Programs/Design for This Report Table 119. Authors List of This Report Table 120. Secondary Sources Table 121. Primary Sources List of Figures Figure 1. Somatostatin Analogue Drug Image Figure 2. Global Somatostatin Analogue Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Somatostatin Analogue Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. Octreotide Image Figure 5. Lanreotide Image Figure 6. Pasireotide Image Figure 7. Global Somatostatin Analogue Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Somatostatin Analogue Drug Market Size Share 2021 VS 2025 VS 2032 Figure 9. Acromegaly Image Figure 10. Neuroendocrine Tumor (NET) Image Figure 11. Others Image Figure 12. Global Somatostatin Analogue Drug Market Size (US$ Million) & (2021-2032) Figure 13. Global Somatostatin Analogue Drug Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Somatostatin Analogue Drug Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Somatostatin Analogue Drug Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Somatostatin Analogue Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Somatostatin Analogue Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Somatostatin Analogue Drug Revenue Market Share by Type (2021-2032) Figure 20. Global Somatostatin Analogue Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Somatostatin Analogue Drug Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Somatostatin Analogue Drug Revenue Market Share by Application (2021-2032) Figure 23. North America Somatostatin Analogue Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Somatostatin Analogue Drug Revenue Share by Type (2021-2032) Figure 25. North America Somatostatin Analogue Drug Revenue Share by Application (2021-2032) Figure 26. North America Somatostatin Analogue Drug Revenue Share by Country (2021-2032) Figure 27. United States Somatostatin Analogue Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Somatostatin Analogue Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Somatostatin Analogue Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Somatostatin Analogue Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Somatostatin Analogue Drug Revenue Share by Type (2021-2032) Figure 32. Europe Somatostatin Analogue Drug Revenue Share by Application (2021-2032) Figure 33. Europe Somatostatin Analogue Drug Revenue Share by Country (2021-2032) Figure 34. Germany Somatostatin Analogue Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Somatostatin Analogue Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Somatostatin Analogue Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Somatostatin Analogue Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Somatostatin Analogue Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Somatostatin Analogue Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Somatostatin Analogue Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Somatostatin Analogue Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Somatostatin Analogue Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Somatostatin Analogue Drug Revenue Share by Type (2021-2032) Figure 44. China Somatostatin Analogue Drug Revenue Share by Application (2021-2032) Figure 45. Asia Somatostatin Analogue Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Somatostatin Analogue Drug Revenue Share by Type (2021-2032) Figure 47. Asia Somatostatin Analogue Drug Revenue Share by Application (2021-2032) Figure 48. Asia Somatostatin Analogue Drug Revenue Share by Region (2021-2032) Figure 49. Japan Somatostatin Analogue Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Somatostatin Analogue Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Somatostatin Analogue Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Somatostatin Analogue Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Somatostatin Analogue Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Somatostatin Analogue Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Somatostatin Analogue Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Somatostatin Analogue Drug Revenue Share by Type (2021-2032) Figure 57. SAMEA Somatostatin Analogue Drug Revenue Share by Application (2021-2032) Figure 58. SAMEA Somatostatin Analogue Drug Revenue Share by Country (2021-2032) Figure 59. Brazil Somatostatin Analogue Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Somatostatin Analogue Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Somatostatin Analogue Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Somatostatin Analogue Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Somatostatin Analogue Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Somatostatin Analogue Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Somatostatin Analogue Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Somatostatin Analogue Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Somatostatin Analogue Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Somatostatin Analogue Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Somatostatin Analogue Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Octreotide
  • Lanreotide
  • Pasireotide
Applications
  • Acromegaly
  • Neuroendocrine Tumor (NET)
  • Others
Companies covered
  • Teva Pharmaceutical Industries Ltd.
  • Novartis AG
  • Eli Lilly & Co.
  • Pfizer Inc.
  • Tarveda Therapeutics Inc.
  • Ipsen Group
  • F. Hoffmann-La Roche Ltd.
  • Chiasma
  • Camurus AB
  • Boehringer Ingelheim International GmbH

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Somatostatin Analogue Drug Market by Type
  3. 1.2.1 Global Somatostatin Analogue Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Octreotide
  5. 1.2.3 Lanreotide
  6. 1.2.4 Pasireotide
  7. 1.3 Somatostatin Analogue Drug Market by Application
  8. 1.3.1 Global Somatostatin Analogue Drug Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Acromegaly
  10. 1.3.3 Neuroendocrine Tumor (NET)
  11. 1.3.4 Others
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Somatostatin Analogue Drug Market Dynamics
  1. 2.1 Somatostatin Analogue Drug Industry Trends
  2. 2.2 Somatostatin Analogue Drug Industry Drivers
  3. 2.3 Somatostatin Analogue Drug Industry Opportunities and Challenges
  4. 2.4 Somatostatin Analogue Drug Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Somatostatin Analogue Drug Market Perspective (2021-2032)
  2. 3.2 Global Somatostatin Analogue Drug Growth Trends by Region
  3. 3.2.1 Global Somatostatin Analogue Drug Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Somatostatin Analogue Drug Market Size by Region (2021-2026)
  5. 3.2.3 Global Somatostatin Analogue Drug Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Somatostatin Analogue Drug Revenue by Players
  2. 4.1.1 Global Somatostatin Analogue Drug Revenue by Players (2021-2026)
  3. 4.1.2 Global Somatostatin Analogue Drug Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Somatostatin Analogue Drug Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Somatostatin Analogue Drug Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Somatostatin Analogue Drug Key Players Headquarters & Area Served
  7. 4.4 Global Somatostatin Analogue Drug Players, Product Type & Application
  8. 4.5 Global Somatostatin Analogue Drug Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Somatostatin Analogue Drug Market CR5 and HHI
  11. 4.6.3 2025 Somatostatin Analogue Drug Tier 1, Tier 2, and Tier 3
5 Somatostatin Analogue Drug Market Size by Type
  1. 5.1 Global Somatostatin Analogue Drug Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Somatostatin Analogue Drug Revenue by Type (2021-2032)
  3. 5.3 Global Somatostatin Analogue Drug Revenue Market Share by Type (2021-2032)
6 Somatostatin Analogue Drug Market Size by Application
  1. 6.1 Global Somatostatin Analogue Drug Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Somatostatin Analogue Drug Revenue by Application (2021-2032)
  3. 6.3 Global Somatostatin Analogue Drug Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Teva Pharmaceutical Industries Ltd.
  2. 7.1.1 Teva Pharmaceutical Industries Ltd. Company Information
  3. 7.1.2 Teva Pharmaceutical Industries Ltd. Business Overview
  4. 7.1.3 Teva Pharmaceutical Industries Ltd. Somatostatin Analogue Drug Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Teva Pharmaceutical Industries Ltd. Somatostatin Analogue Drug Product Portfolio
  6. 7.1.5 Teva Pharmaceutical Industries Ltd. Recent Developments
  7. 7.2 Novartis AG
  8. 7.2.1 Novartis AG Company Information
  9. 7.2.2 Novartis AG Business Overview
  10. 7.2.3 Novartis AG Somatostatin Analogue Drug Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Novartis AG Somatostatin Analogue Drug Product Portfolio
  12. 7.2.5 Novartis AG Recent Developments
  13. 7.3 Eli Lilly & Co.
  14. 7.3.1 Eli Lilly & Co. Company Information
  15. 7.3.2 Eli Lilly & Co. Business Overview
  16. 7.3.3 Eli Lilly & Co. Somatostatin Analogue Drug Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Eli Lilly & Co. Somatostatin Analogue Drug Product Portfolio
  18. 7.3.5 Eli Lilly & Co. Recent Developments
  19. 7.4 Pfizer Inc.
  20. 7.4.1 Pfizer Inc. Company Information
  21. 7.4.2 Pfizer Inc. Business Overview
  22. 7.4.3 Pfizer Inc. Somatostatin Analogue Drug Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Pfizer Inc. Somatostatin Analogue Drug Product Portfolio
  24. 7.4.5 Pfizer Inc. Recent Developments
  25. 7.5 Tarveda Therapeutics Inc.
  26. 7.5.1 Tarveda Therapeutics Inc. Company Information
  27. 7.5.2 Tarveda Therapeutics Inc. Business Overview
  28. 7.5.3 Tarveda Therapeutics Inc. Somatostatin Analogue Drug Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Tarveda Therapeutics Inc. Somatostatin Analogue Drug Product Portfolio
  30. 7.5.5 Tarveda Therapeutics Inc. Recent Developments
  31. 7.6 Ipsen Group
  32. 7.6.1 Ipsen Group Company Information
  33. 7.6.2 Ipsen Group Business Overview
  34. 7.6.3 Ipsen Group Somatostatin Analogue Drug Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Ipsen Group Somatostatin Analogue Drug Product Portfolio
  36. 7.6.5 Ipsen Group Recent Developments
  37. 7.7 F. Hoffmann-La Roche Ltd.
  38. 7.7.1 F. Hoffmann-La Roche Ltd. Company Information
  39. 7.7.2 F. Hoffmann-La Roche Ltd. Business Overview
  40. 7.7.3 F. Hoffmann-La Roche Ltd. Somatostatin Analogue Drug Revenue and Gross Margin (2021-2026)
  41. 7.7.4 F. Hoffmann-La Roche Ltd. Somatostatin Analogue Drug Product Portfolio
  42. 7.7.5 F. Hoffmann-La Roche Ltd. Recent Developments
  43. 7.8 Chiasma
  44. 7.8.1 Chiasma Company Information
  45. 7.8.2 Chiasma Business Overview
  46. 7.8.3 Chiasma Somatostatin Analogue Drug Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Chiasma Somatostatin Analogue Drug Product Portfolio
  48. 7.8.5 Chiasma Recent Developments
  49. 7.9 Camurus AB
  50. 7.9.1 Camurus AB Company Information
  51. 7.9.2 Camurus AB Business Overview
  52. 7.9.3 Camurus AB Somatostatin Analogue Drug Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Camurus AB Somatostatin Analogue Drug Product Portfolio
  54. 7.9.5 Camurus AB Recent Developments
  55. 7.10 Boehringer Ingelheim International GmbH
  56. 7.10.1 Boehringer Ingelheim International GmbH Company Information
  57. 7.10.2 Boehringer Ingelheim International GmbH Business Overview
  58. 7.10.3 Boehringer Ingelheim International GmbH Somatostatin Analogue Drug Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Boehringer Ingelheim International GmbH Somatostatin Analogue Drug Product Portfolio
  60. 7.10.5 Boehringer Ingelheim International GmbH Recent Developments
8 North America
  1. 8.1 North America Somatostatin Analogue Drug Revenue (2021-2032)
  2. 8.2 North America Somatostatin Analogue Drug Revenue by Type (2021-2032)
  3. 8.2.1 North America Somatostatin Analogue Drug Revenue by Type (2021-2026)
  4. 8.2.2 North America Somatostatin Analogue Drug Revenue by Type (2027-2032)
  5. 8.3 North America Somatostatin Analogue Drug Revenue Share by Type (2021-2032)
  6. 8.4 North America Somatostatin Analogue Drug Revenue by Application (2021-2032)
  7. 8.4.1 North America Somatostatin Analogue Drug Revenue by Application (2021-2026)
  8. 8.4.2 North America Somatostatin Analogue Drug Revenue by Application (2027-2032)
  9. 8.5 North America Somatostatin Analogue Drug Revenue Share by Application (2021-2032)
  10. 8.6 North America Somatostatin Analogue Drug Revenue by Country
  11. 8.6.1 North America Somatostatin Analogue Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Somatostatin Analogue Drug Revenue by Country (2021-2026)
  13. 8.6.3 North America Somatostatin Analogue Drug Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Somatostatin Analogue Drug Revenue (2021-2032)
  2. 9.2 Europe Somatostatin Analogue Drug Revenue by Type (2021-2032)
  3. 9.2.1 Europe Somatostatin Analogue Drug Revenue by Type (2021-2026)
  4. 9.2.2 Europe Somatostatin Analogue Drug Revenue by Type (2027-2032)
  5. 9.3 Europe Somatostatin Analogue Drug Revenue Share by Type (2021-2032)
  6. 9.4 Europe Somatostatin Analogue Drug Revenue by Application (2021-2032)
  7. 9.4.1 Europe Somatostatin Analogue Drug Revenue by Application (2021-2026)
  8. 9.4.2 Europe Somatostatin Analogue Drug Revenue by Application (2027-2032)
  9. 9.5 Europe Somatostatin Analogue Drug Revenue Share by Application (2021-2032)
  10. 9.6 Europe Somatostatin Analogue Drug Revenue by Country
  11. 9.6.1 Europe Somatostatin Analogue Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Somatostatin Analogue Drug Revenue by Country (2021-2026)
  13. 9.6.3 Europe Somatostatin Analogue Drug Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Somatostatin Analogue Drug Revenue (2021-2032)
  2. 10.2 China Somatostatin Analogue Drug Revenue by Type (2021-2032)
  3. 10.2.1 China Somatostatin Analogue Drug Revenue by Type (2021-2026)
  4. 10.2.2 China Somatostatin Analogue Drug Revenue by Type (2027-2032)
  5. 10.3 China Somatostatin Analogue Drug Revenue Share by Type (2021-2032)
  6. 10.4 China Somatostatin Analogue Drug Revenue by Application (2021-2032)
  7. 10.4.1 China Somatostatin Analogue Drug Revenue by Application (2021-2026)
  8. 10.4.2 China Somatostatin Analogue Drug Revenue by Application (2027-2032)
  9. 10.5 China Somatostatin Analogue Drug Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Somatostatin Analogue Drug Revenue (2021-2032)
  2. 11.2 Asia Somatostatin Analogue Drug Revenue by Type (2021-2032)
  3. 11.2.1 Asia Somatostatin Analogue Drug Revenue by Type (2021-2026)
  4. 11.2.2 Asia Somatostatin Analogue Drug Revenue by Type (2027-2032)
  5. 11.3 Asia Somatostatin Analogue Drug Revenue Share by Type (2021-2032)
  6. 11.4 Asia Somatostatin Analogue Drug Revenue by Application (2021-2032)
  7. 11.4.1 Asia Somatostatin Analogue Drug Revenue by Application (2021-2026)
  8. 11.4.2 Asia Somatostatin Analogue Drug Revenue by Application (2027-2032)
  9. 11.5 Asia Somatostatin Analogue Drug Revenue Share by Application (2021-2032)
  10. 11.6 Asia Somatostatin Analogue Drug Revenue by Country
  11. 11.6.1 Asia Somatostatin Analogue Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Somatostatin Analogue Drug Revenue by Country (2021-2026)
  13. 11.6.3 Asia Somatostatin Analogue Drug Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Somatostatin Analogue Drug Revenue (2021-2032)
  2. 12.2 SAMEA Somatostatin Analogue Drug Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Somatostatin Analogue Drug Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Somatostatin Analogue Drug Revenue by Type (2027-2032)
  5. 12.3 SAMEA Somatostatin Analogue Drug Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Somatostatin Analogue Drug Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Somatostatin Analogue Drug Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Somatostatin Analogue Drug Revenue by Application (2027-2032)
  9. 12.5 SAMEA Somatostatin Analogue Drug Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Somatostatin Analogue Drug Revenue by Country
  11. 12.6.1 SAMEA Somatostatin Analogue Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Somatostatin Analogue Drug Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Somatostatin Analogue Drug Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst